Recombinant protein s composition
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsYutaka KANDA, Hiroshi SATO, Tsuyoshi YAMADA, Akifumi KATO, Mitsuo SATOH
Life of this patent
Estimating the term…
Loading patent…
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsYutaka KANDA, Hiroshi SATO, Tsuyoshi YAMADA, Akifumi KATO, Mitsuo SATOH
Estimating the term…
A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.
A Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.
Dependencies are inferred from the claim text.